Plexxikon Deals Kidney Disease Drug To Roche (Updated)
This article was originally published in The Pink Sheet Daily
Executive Summary
With a three-year financial runway, biotech contends the deal validates its discovery-only business model.
You may also be interested in...
Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
The $100 Million IND
An extraordinary series of high-value IND-stage deals could help to solve what has always been the intractable problem for biotechs: how to fund late-stage product development and simultaneously re-fill the early-stage pipeline. Still, it will be the rare biotech that can pull off this strategy--which requires INDs in the hottest areas of pharmaceutical development.